Research map: Clinical Development, Regulatory, and Reimbursement Review Duration of New Drugs in the US and European Countries

Back to the article

Papers in this map

  1. Clinical development times for innovative drugs · Dean G. Brown · 2021 · 177 citations · Cited by this paper
  2. JAMA Health Forum · 2026 · Related
  3. Clinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval · Ian T. T. Liu · 2024 · 127 citations · Cited by this paper
  4. Error in Table 3 · 2026 · Related
  5. Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study · Thomas J. Hwang · 2020 · 110 citations · Cited by this paper
  6. Medicaid Expansion and Mortality Among Formerly Incarcerated Individuals · 2026 · Related
  7. The FDA’s Expedited Programs and Clinical Development Times for Novel Therapeutics, 2012-2016 · Thomas J. Hwang · 2017 · 85 citations · Cited by this paper
  8. Making the FDA Great Again · 2026 · Related
  9. Comparison of Uptake and Prices of Biosimilars in the US, Germany, and Switzerland · David Carl · 2022 · 64 citations · Cited by this paper
  10. Losing Our Lens on Maternal and Infant Health—The Consequences of Disrupting PRAMS · 2026 · Related
  11. Therapeutic Value of Drugs Granted Accelerated Approval or Conditional Marketing Authorization in the US and Europe From 2007 to 2021 · Kerstin Noëlle Vokinger · 2022 · 55 citations · Cited by this paper
  12. Product Reformulation in Response to the 2016 FDA Updated Nutrition Facts Label · 2026 · Related
  13. Analysis of FDA's Accelerated Approval Program Performance December 1992–December 2021 · Ginny Beakes-Read · 2022 · 50 citations · Cited by this paper
  14. Ultralow-Volume Treatments for Mosquito-Borne Diseases · 2026 · Related
  15. Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia · Thomas J. Hwang · 2022 · 46 citations · Cited by this paper
  16. State-Level Abortion Bans and the OBGYN Workforce · 2026 · Related
  17. One Pivotal Trial, the New Default Option for FDA Approval — Ending the Two-Trial Dogma · Vinay Prasad · 2026 · 36 citations · Cited by this paper
  18. Institutional Variation in Life-Sustaining Treatments and Mortality Among Older Patients · 2026 · Related
  19. Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment · Robin Forrest · 2024 · 29 citations · Cited by this paper
  20. Trends and Factors in Nursing Home Closures · 2026 · Related
  21. Coverage of Novel Therapeutic Agents by Medicare Prescription Drug Plans Following FDA Approval · Daniel L Shaw · 2018 · 26 citations · Cited by this paper
  22. Refreshing the biologic pipeline 2020 · John Hodgson · 2021 · 19 citations · Cited by this paper
  23. Regulatory Review Duration and Differences in Submission Times of Drugs in the United States and Europe, 2011 to 2020 · Kerstin Noëlle Vokinger · 2023 · 18 citations · Cited by this paper
  24. Time intervals between U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) new cancer therapy approvals. · Mark Peter Lythgoe · 2021 · 16 citations · Cited by this paper
  25. Patients’ access to drugs with rebates in Switzerland – Empirical analysis and policy implications for drug pricing in Europe · David Carl · 2021 · 12 citations · Cited by this paper
  26. Time From Approval to Reimbursement of New Drugs: A Comparative Analysis Between the United States, England, Germany, France, and Switzerland (2011–2022) · C. Glaus · 2024 · 5 citations · Cited by this paper
  27. Does Firm’s Alliances Increase New Drug Development Time? A Multiple Regression Analysis of Clinical Development Time · Ho-Kyoung Kim · 2023 · 4 citations · Cited by this paper
  28. 2281MO Trial duration of cancer drugs: Effects of geographic scope and endpoint selection · S. Hediger · 2025 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)